122 related articles for article (PubMed ID: 12412792)
1. The role of estrogens and related compounds in the management of primary hyperparathyroidism.
Marcus R
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N146-9. PubMed ID: 12412792
[No Abstract] [Full Text] [Related]
2. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.
Zanchetta JR; Bogado CE
J Bone Miner Res; 2001 Jan; 16(1):189-90. PubMed ID: 11149484
[No Abstract] [Full Text] [Related]
3. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
Ohta H
Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
[TBL] [Abstract][Full Text] [Related]
4. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
5. Drugs for prevention and treatment of postmenopausal osteoporosis.
Treat Guidel Med Lett; 2002 Nov; 1(3):13-8. PubMed ID: 15529101
[No Abstract] [Full Text] [Related]
6. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women.
Klein KP; Herrington DM
Medscape Womens Health; 2002; 7(5):2. PubMed ID: 12466731
[No Abstract] [Full Text] [Related]
7. Estrogens and progestins in the management of primary hyperparathyroidism.
Marcus R
J Bone Miner Res; 1991 Oct; 6 Suppl 2():S125-9; discussion S151-2. PubMed ID: 1763663
[TBL] [Abstract][Full Text] [Related]
8. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
9. [Raloxifene and bone quality issues].
Ohta H
Clin Calcium; 2005 Jun; 15(6):1012-9. PubMed ID: 15930716
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
Bjarnason NH
Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050
[No Abstract] [Full Text] [Related]
11. Management of osteoporosis in Hong Kong.
Kung AW
Clin Calcium; 2004 Sep; 14(9):108-11. PubMed ID: 15577121
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of osteoporosis].
Lakatos P
Orv Hetil; 2003 Aug; 144(31):1551-2. PubMed ID: 14502870
[No Abstract] [Full Text] [Related]
13. [Who are the candidates for the treatment by raloxifen ?].
Hagino H
Clin Calcium; 2004 Oct; 14(10):111-3. PubMed ID: 15577141
[TBL] [Abstract][Full Text] [Related]
14. Current pharmacological options for the management of primary hyperparathyroidism.
Vestergaard P
Drugs; 2006; 66(17):2189-211. PubMed ID: 17137403
[TBL] [Abstract][Full Text] [Related]
15. [SERM and quality of bone].
Sohen S
Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
[TBL] [Abstract][Full Text] [Related]
16. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
17. [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
Ohnaka K; Takayanagi R
Clin Calcium; 2009 Aug; 19(8):1118-24. PubMed ID: 19638695
[TBL] [Abstract][Full Text] [Related]
18. Preventing osteoporosis: the new significance of hyperparathyroidism.
Avioli LV
Geriatrics; 1986 Oct; 41(10):30-7. PubMed ID: 3758680
[TBL] [Abstract][Full Text] [Related]
19. The rise of raloxifene and the fall of invasive breast cancer.
Jordan VC
J Natl Cancer Inst; 2008 Jun; 100(12):831-3. PubMed ID: 18544739
[No Abstract] [Full Text] [Related]
20. [Parathyroid and bone. Medical management of primary hyperparathyroidism].
Komatsu Y
Clin Calcium; 2007 Dec; 17(12):1902-8. PubMed ID: 18057667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
